- Strong epidemiological, genetic and cellular evidence links immune dysregulation with depression and psychosis, but causality remains unresolved and biomarkers lack clinical utility.
- Novel methods, including target trial emulation on observational data and functional genomics, offer avenues for precision immunopsychiatry and patient stratification.
- Future research must prioritise causal inference, validated immune biomarkers and translational trials to enable stratified immunomodulatory treatments in psychiatric disorders.
Br J Psychiatry. 2026 Sep 8:1-3. doi: 10.1192/bjp.2026.10761. Online ahead of print.
ABSTRACT
Despite compelling epidemiological, genetic and cellular evidence linking immune dysregulation to depression and schizophrenia (and other psychotic disorders), causality remains contested and no immune biomarker has yet demonstrated robust clinical utility. Emerging methodological approaches – from target trial emulation on observational data to functional genomics – offer a potential path towards precision immunopsychiatry and stratified immunomodulatory treatment.
PMID:42708395 | DOI:10.1192/bjp.2026.10761
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

